Debbane Raymond's Form 4 filing
Lexicon Pharmaceuticals, Inc. (LXRX) · filed Feb 4, 2026
- Accession no.
- 0001193125-26-037644
- Filed
- Feb 4, 2026, 4:25 PM ET
- Trade date
- Feb 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $2.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Debbane RaymondCIK 0001053890 | Director |
| Artal Group S.A.CIK 0001053906 | Director, 10% Owner |
| Artal International S.C.A.CIK 0001218180 | Director, 10% Owner |
| Westend S.A.CIK 0001283968 | Director, 10% Owner |
| Stichting Administratiekantoor WestendCIK 0001460840 | Director, 10% Owner |
| Artal International Management S.A.CIK 0001522131 | Director, 10% Owner |
| Siren, L.L.C.CIK 0002005245 | Director, 10% Owner |
| Invus Global Management, LLCCIK 0002005369 | Director, 10% Owner |
| Artal Participations S.a r.l.CIK 0002048403 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | AGrant or awardAcquired | +18,553,846 | $1.30 | +$24,119,999.8 | 154,734,327 | Indirect | |
| Feb 2, 2026 | Common Stock | AGrant or awardAcquired | +3,846,154 | $1.30 | +$5,000,000.2 | 7,362,368 | Indirect | |
| Feb 2, 2026 | Common Stock | PPurchaseAcquired | +1,538,462 | $1.30 | +$2,000,000.6 | 1,538,462 | Indirect | |
| Feb 2, 2026 | Series B Convertible Preferred Stock | AGrant or awardAcquired | +367,145.12 | $65.00 | +$23,864,432.8 | 367,145.12 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.